Señales en vivo de IMPL | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 dic 2023 @ 15:58):

Stats
Volumen de hoy	720 030
Volumen promedio	1.02M
Capitalización de mercado	956 000
EPS	$0 ( 2024-03-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0128
ATR14	$0.116 (114.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Smith Brandon D	Buy	0
2023-12-15	Vivo Capital Viii, Llc	Sell	87 934	Common Stock
2023-12-18	Vivo Capital Viii, Llc	Sell	209 029	Common Stock
2023-12-19	Vivo Capital Viii, Llc	Sell	208 657	Common Stock
2023-12-15	Vivo Capital Viii, Llc	Sell	12 066	Common Stock

INSIDER POWER
47.38
Last 95 transactions
Buy: 8 739 782 \| Sell: 5 181 184

Volumen Correlación

Largo: 0.42 (neutral)

Corto: -0.39 (neutral)

Signal:(41.758) Neutral

Impel Pharmaceuticals Correlación

10 Correlaciones Más Positivas
FNWB	0.921
EGBN	0.909
CNSL	0.904
DIBS	0.901
ALTO	0.896
FTXO	0.892
FFIC	0.885
FRST	0.883
CSTE	0.881
CCSI	0.88

10 Correlaciones Más Negativas
LMNR	-0.937
WIRE	-0.927
NRDS	-0.918
MHUA	-0.893
PEGA	-0.892
SKYT	-0.889
OBT	-0.889
MORF	-0.886
HTBI	-0.884
HUGE	-0.882

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Impel Pharmaceuticals Correlación - Moneda/Commodity

0.45
( neutral )

0.62
( weak )

0.00
( neutral )

0.64
( weak )

0.21
( neutral )

-0.57
( weak negative )

Impel Pharmaceuticals Finanzas

Annual	2022
Ingresos:	$12.65M
Beneficio Bruto:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2022
Ingresos:	$12.65M
Beneficio Bruto:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2021
Ingresos:	$668 000
Beneficio Bruto:	$-23 000.00 (-3.44 %)
EPS:	$-5.25

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Impel Pharmaceuticals

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.